Intuitive Surgical Inc

Intuitive Surgical reported second-quarter 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. The company's share price is down 28.6% year to date, with a one-year total shareholder return decline of 16.1%, though the recent seven-day return of 8.95% and three-year total shareholder return of 30.9% suggest longer-term holders have still seen gains. A community narrative pegs Intuitive Surgical's fair value at $630.48 versus the last close of $401.23, implying the stock is 36.4% undervalued, but the current P/E of 45.2x is well above the U.S. Medical Equipment industry at 26.3x and the peer average at 28.8x.

Johnson & Johnson has received FDA De Novo authorization for its OTTAVA robotic surgical system, marking its official entry into the U.S. soft-tissue robotic surgery market. The system features a table-integrated design that occupies 30% to 50% less space than traditional systems, and is authorized for multiple upper-abdominal general surgery procedures including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair. Johnson & Johnson will begin a selective commercial launch with select U.S. customers, while also advancing the technology into additional regulatory jurisdictions and indications, with an ongoing clinical trial for inguinal hernia procedures. The company enters a market dominated by Intuitive Surgical, which had an installed base of 11,710 da Vinci systems at the end of the second quarter of 2026 and reported $2.89 billion in revenue for the quarter, up 19% year-over-year.

Intuitive Surgical has approved amendments to its bylaws that update shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals, including tougher solicitation thresholds, more detailed disclosure on synthetic equity and investment intent, and caps on nominee numbers. These changes raise the bar for activist campaigns, potentially reducing short-term pressure on management decisions while making it harder for dissatisfied holders to push for changes. The next test will be the 2027 proxy season, when investors can track whether any shareholder proposals or contests clear the 67% solicitation requirement and how turnout and vote splits compare with recent annual meetings.

Jim Cramer highlighted the FDA's De Novo marketing authorization for Johnson & Johnson's OTTAVA Robotic Surgical System as the catalyst that forced investors to recognize the healthcare giant as a high-tech innovator. The approval, announced on July 22, 2026, covers a range of general upper-abdominal procedures and marks the world's first table-integrated soft-tissue robotic platform. Cramer had been urging investors to accumulate JNJ stock after a strong earnings report that Wall Street initially dismissed, and the OTTAVA news sent the stock surging. He views holding JNJ as a portfolio 'permit' that allows investors to safely own aggressive tech growth while protecting against market pullbacks. Institutional holders control roughly 77% of JNJ shares, with 113 hedge funds holding positions in Q1 2026, and short interest remains minimal at 1.14%.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

Intuitive Surgical and Medtronic both reported better-than-expected quarterly results, yet each faces distinct challenges that cloud their growth outlooks. Intuitive Surgical posted fiscal Q2 2026 revenue of $2.89 billion, up 19%, with adjusted EPS of $2.80 beating estimates by $0.30, but its stock fell on concerns over slowing domestic procedure growth. Medtronic reported its highest annual revenue growth in a decade, with fiscal Q4 revenue reaching $9.8 billion and full-year adjusted revenue of $36.3 billion, driven by a 78% global surge in Cardiac Ablation Solutions. Both companies warned that tariffs are a material headwind: Medtronic absorbed a $74 million impact in the latest period and expects roughly $250 million in fiscal 2027, while Intuitive Surgical cautioned that additional tariffs could materially alter its financial results. Intuitive Surgical maintained its 2026 da Vinci procedure growth guidance of 13.5% to 15.5%, and Medtronic guided for fiscal 2027 organic revenue growth of 6.75% to 7.25%.

Intuitive Surgical reported second-quarter 2026 revenue of $2.89 billion, up 18.4% year-over-year, and adjusted earnings per share of $2.80, beating consensus by $0.30, yet its stock sold off sharply as U.S. da Vinci procedure growth moderated to 12% year-over-year. Worldwide procedure growth reached 16%, gross margin expanded to 70.0% on a non-GAAP basis, and the company placed 468 da Vinci systems, an 18% increase. Management reaffirmed full-year 2026 worldwide da Vinci procedure growth of 13.5% to 15.5% and raised its non-GAAP gross margin guidance to 68.0% to 69.0%, while some analysts flagged headwinds from the expiry of enhanced ACA tax credits and a structural decline in bariatric procedures tied to GLP-1 drugs. Seeking Alpha's quant system rates the stock a Hold, with an A+ in profitability but a D- in valuation and a D in momentum following a post-earnings decline of 9% to 14%.

Intuitive Surgical shares have fallen 37% year to date to $356.83, even after the company beat second-quarter estimates for the fifth straight quarter with revenue of $2.89 billion and non-GAAP earnings per share of $2.80. Management cut full-year da Vinci procedure growth guidance to 13.5% to 15.5% from 18% in 2025, citing softer U.S. procedure growth, GLP-1-related bariatric case declines, and China tender softness, which sent shares down 11% the day after earnings. Bernstein, the most bullish analyst, maintains an Outperform rating with a $685 price target, implying nearly 92% upside, while the average Wall Street target is $484.40. The company repurchased $379 million of stock in the second quarter at an average price of $439, above current levels, and holds $8.6 billion in cash. Peer medtech stocks Medtronic and Stryker are down only 11% and 4% year to date, respectively, making Intuitive Surgical's decline a single-name reset with the widest analyst-implied upside in the group.

UnitedHealth Group and Intuitive Surgical both reported earnings that beat Wall Street expectations in the same week of July, yet their stocks moved in opposite directions. UnitedHealth posted adjusted earnings of $6.38 a share versus the $4.90 expected, with revenue rising to $112 billion, and raised its full-year profit forecast to $19.50 to $20 a share, sending its stock up as much as 8%. Intuitive Surgical saw revenue rise 19% to $2.89 billion and adjusted profit of $2.80 a share against the $2.50 estimate, but its stock fell as much as 13% after the company said it now expects full-year procedure growth near the middle of its unchanged 13.5% to 15.5% range, rather than the higher end previously implied. The medical cost ratio at UnitedHealth improved to 86.7% from 89.4% a year ago, while Intuitive Surgical confirmed that insurance-driven delays in care and GLP-1 weight-loss drugs are cutting into bariatric surgery volume, with U.S. procedure growth slowing to 12% from 14% in the prior quarter. Hedge fund data from Insider Monkey showed both stocks losing support before the reports, with UnitedHealth held by 130 funds at the end of the first quarter of 2026, down from 145, and Intuitive Surgical held by 103 funds, down from 109.

Intuitive Surgical shares fell more than 12% before the bell on July 17 after the company acknowledged that the expiration of enhanced Affordable Care Act subsidies is affecting demand for elective procedures performed with its da Vinci surgical robots. US da Vinci procedure growth slowed to roughly 12% in the second quarter, below the company’s expectations at the start of the year, with CEO David Rosa noting that fluctuating patient coverage and premium dynamics influence when patients seek care. The selloff occurred despite Intuitive beating consensus estimates for revenue, earnings, system placements, and procedure growth in the same quarter, and maintaining its global procedure-growth forecast. The company’s results appear to support HCA Healthcare’s earlier warning of lower surgical demand and rising uninsured patients, contradicting Abbott’s view that blaming industry-wide weakness on ACA disenrollment was a flawed assumption. Stifel cut its price target on Intuitive to $550 from $670 while keeping a Buy rating, and the stock’s forward P/E ratio has fallen to about 33x, near the low end of its five-year range and roughly in line with the medical device peer group average.

Johnson & Johnson announced on the 22nd that it has received marketing approval from the U.S. Food and Drug Administration for its surgical robot Ottava, entering the soft-tissue surgical robot market. The approval covers upper abdominal general surgery procedures such as gastric bypass and gallbladder removal. J&J plans to begin sales at select U.S. medical institutions, with plans for expanded indications and overseas deployment including Japan and Western Europe. The market is currently dominated by Intuitive Surgical's da Vinci, while Medtronic's Hugo also received U.S. approval last year. J&J's surgical business head stated the company intends to lead the surgical robotics field, challenging its competitors.

Intuitive Surgical shares have fallen 38% year-to-date to a multi-year low last seen in early 2024, even after the company reported second-quarter revenue of $2.9 billion, a 19% year-over-year increase. The number of da Vinci procedures rose 15% and the installed base grew 12% to 11,710 systems. CFO Jamie Samath noted that the expiration of Affordable Care Act enhanced premiums had a modest adverse impact on procedures, while a decline in bariatric cases tied to GLP-1 weight loss drugs also weighed on sentiment. The stock now trades at 33 times estimated future earnings, down from multiples as high as around 70 in the past.

Intuitive Surgical shares have fallen 38% year-to-date to a multi-year low not seen since early 2024, even after the company reported second-quarter revenue of $2.9 billion, a 19% year-over-year increase. The number of da Vinci procedures rose 15% and the installed base grew 12% to 11,710 systems, but the stock has been pressured by the expiration of Affordable Care Act enhanced premiums and a decline in bariatric cases linked to rising GLP-1 use. The sell-off has pushed the stock's forward earnings multiple down to 33 times, well below historical levels that often reached around 70, potentially making it a more attractive entry point for long-term investors.

US stock futures pointed lower Monday morning, with E mini S&P 500 contracts down around 1%, as investors weighed falling bond yields against a cooling housing backdrop. The US 10 year Treasury yield slipped to about 4.5% after softer inflation readings, while pending home sales dropped 5.4% in June and 30 year mortgage rates sat at 6.55%. Among top movers, Travelers Companies jumped 9.22% after Q2 earnings, dividend affirmation, and a buyback update, while Intuitive Surgical fell 14.15% after multiple analysts cut price targets following Q2 results and slower procedure growth. On the radar, earnings from Alphabet, Tesla, General Motors, and housing-linked stocks are due over the next three sessions.

Intuitive Surgical shares fell this week after the company issued a tepid forecast for the rest of 2026 despite strong second-quarter results. Worldwide procedures rose 16% year over year, with da Vinci procedures up 15% and Ion procedures surging 36%. Revenue climbed 19% to $2.9 billion, and adjusted net income grew 25% to $1 billion, or $2.80 per share, beating Wall Street estimates of $2.50. However, management guided for full-year da Vinci procedure growth at the midpoint of its previously issued range of 13.5% to 15.5%, implying slower expansion in the second half. Wall Street responded with multiple price target cuts, prompting a sell-off.

Shares of several medical device companies fell after Intuitive Surgical warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. STAAR Surgical dropped 10.1%, Globus Medical fell 4.4%, Integer Holdings declined 4.1%, and Enovis lost 5.1%. The warning suggests that shifting insurance coverage could dampen the number of medical procedures performed in the United States, creating headwinds for the entire industry reliant on steady procedure volumes.

Intuitive Surgical shares fell 11.41% to a 52-week low after the company reported second-quarter results that beat Wall Street estimates. Revenue rose 19% to $2.89 billion and non-GAAP earnings reached $2.80 per share, compared with $2.19 a year earlier, exceeding analyst forecasts of $2.51 per share on revenue of $2.82 billion. Worldwide procedures grew about 16%, and the company placed 468 da Vinci systems, including 246 of its newest da Vinci 5, up from 180 a year ago, expanding the installed base 12% to 11,710 systems. Non-GAAP EPS included an $0.08 benefit from tariff refunds, implying underlying earnings closer to $2.72, while gross margin hit 70.0% in the quarter but full-year guidance was set at 68.0% to 69.0%, reflecting an estimated one percentage point of tariff drag. Intuitive held its full-year procedure growth forecast at 13.5% to 15.5%, a step down from the 16% posted this quarter, and ended the period debt-free with $8.63 billion in cash and investments after repurchasing $0.38 billion of stock.

U.S. stock futures pointed to sharp losses on Friday, with Netflix and Intuitive Surgical among the biggest premarket decliners. S&P 500 futures dropped 67 points, or 0.9%, Nasdaq 100 futures tumbled 490 points, or 1.7%, and Dow futures fell 331 points, or 0.6%, as investors continued to reassess technology valuations. Netflix slid 9.3% after reporting second-quarter revenue of $12.56 billion that narrowly missed estimates and issuing weaker-than-expected third-quarter guidance. Intuitive Surgical fell more than 12% after maintaining its full-year procedure growth outlook for its da Vinci robotic surgery platform and warning that changes to certain U.S. insurance plans could weigh on demand. Other notable movers included Regenxbio, which slumped 16.6% on a $100 million public offering, and Autoliv, down 5.8% after a restructuring charge of roughly $142 million tied to closing manufacturing operations in Türkiye.

Netflix dropped more than 10% in premarket trading after its second-quarter results failed to impress investors, while Intuitive Surgical fell more than 11% despite beating estimates. Netflix earned 80 cents per share on revenue of $12.56 billion, compared to analyst expectations of 79 cents per share on $12.59 billion, and said it would reduce the frequency of its engagement reports. Intuitive Surgical posted adjusted earnings of $2.80 per share on $2.89 billion in revenue, above forecasts of $2.50 per share on $2.82 billion, but maintained its full-year procedure growth outlook of around 14%. Alphabet slid 1.5%, extending Thursday's 4.5% drop after a report that Google is months behind on its latest Gemini AI model. SpaceX fell more than 3.5% after aborting a Starship launch due to engine issues, with CEO Elon Musk saying another attempt would come in days. Verizon Communications rose 1% on plans to sell 274 retail stores and cut about 500 jobs as part of restructuring. BP and ConocoPhillips each gained more than 1% on news they will announce billions of dollars in new Iraq investments. Truist Financial added 1.4% after beating earnings estimates with $1.23 per share versus the $1.08 consensus. Alcoa slipped 0.5% despite topping forecasts with adjusted earnings of $2.12 per share on $3.97 billion in revenue, while lowering its 2026 alumina production outlook. Software stocks broadly declined, with the iShares Expanded Tech-Software Sector ETF down more than 1.5% and names like Salesforce, Palantir, ServiceNow, and Microsoft all lower. Memory stocks continued to unwind, as the Roundhill Memory ETF fell more than 3% and was on track for a 19% weekly loss, with Western Digital, Micron, and Seagate all declining. Fifth Third Bancorp edged higher even after a slight earnings miss, as net interest income rose 48% year-over-year and met expectations.

Stock futures edged lower early Friday as a major correction in the semiconductor space overshadowed a supportive domestic inflation backdrop. Netflix shares plunged 10% after the streaming giant reported mixed second-quarter results, with revenue narrowly missing expectations and full-year revenue guidance of 51.0 billion to 51.4 billion dollars coming in below the 51.4 billion dollar consensus. SpaceX fell 5% after an automatic launch abort of its upgraded Starship V3 rocket extended a five-day losing streak that pushed shares further below their 135 dollar IPO price. STAAR Surgical tumbled 12% despite preliminary second-quarter revenue of more than 90 million dollars roughly doubling year-over-year, as investors focused on geopolitical headwinds and operational challenges from an ERP system implementation. Intuitive Surgical slipped 9% even after beating earnings and revenue expectations, as the company maintained its full-year da Vinci procedure growth outlook of 13.5% to 15.5% and flagged tariff-related margin pressure.

Intuitive Surgical shares dropped 6.3% following a voluntary Class II worldwide recall of certain da Vinci surgical system components due to an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. The recall adds to operational scrutiny ahead of the company's upcoming earnings report, with markets focused on procedure trends and margins. Intuitive Surgical reported first-quarter 2026 revenue of US$2,770.8 million and net income of US$821.5 million, with net margins above 28%, supporting consensus expectations for mid-teens revenue growth. The stock is down about 31% year to date, and the recall raises questions about how operational risks and innovation investments may influence the company's longer-term growth profile.

Evercore ISI lowered its price target on Intuitive Surgical to $430 from $480 while maintaining an In Line rating. The firm's second-quarter preview for MedTech, Life Sciences Tools, and Diagnostics indicates stable demand with healthy procedure volumes and continued equipment spending. Intuitive Surgical is set to report its second-quarter fiscal 2026 earnings on July 16, having previously guided for full-year da Vinci procedure growth of 13.5% to 15.5% and a non-GAAP gross profit margin between 67.5% and 68.5% of revenue.